Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Med Princ Pract ; 25(4): 388-90, 2016.
Article in English | MEDLINE | ID: mdl-27165056

ABSTRACT

OBJECTIVE: To report on the clinical benefits of platelet gel application in a non-regenerating skin wound. CLINICAL PRESENTATION AND INTERVENTION: An 84-year-old man presented with a severe wound with a regular circumference in the frontal region which resulted in a complete loss of epidermis and dermis. The skin lesion, induced by cryosurgery used to remove a basal-cell carcinoma, had previously been treated with a dermal substitute application (Integra®). After the failure of the skin graft, the patient was treated using a platelet gel therapeutic protocol which achieved the complete healing of the injured area. CONCLUSION: This case showed the clinical efficacy of using platelet gel in this elderly patient in whom the dermal substitute graft had been ineffective.


Subject(s)
Blood Platelets , Gels/therapeutic use , Skin, Artificial , Wounds and Injuries/physiopathology , Wounds and Injuries/therapy , Aged, 80 and over , Cryosurgery/adverse effects , Gels/administration & dosage , Humans , Male , Wounds and Injuries/etiology
2.
Clin Immunol ; 157(1): 1-15, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25576661

ABSTRACT

Genome-wide association studies have revealed several genes predisposing to autoimmunity, however, concordance rates in monozygotic twins are significantly below 50% for several autoimmune diseases. The limited presence of a strong genetic association only in some patients supports that other non-genetic mechanisms are active in these pathologies. Epigenetic modifications such as DNA methylation, histone modification, and microRNA signaling regulate gene expression and are sensitive to external stimuli and they might be as bridging between genetic and environmental factors. Some evidence has highlighted the involvement of epigenetic alterations in the pathogenesis of various autoimmune diseases giving rise to great expectations among clinicians and researchers. The direct role of these alterations in the initiation/progression of autoimmune diseases is still unclear. The knowledge in depth of these pathogenic and epigenetic mechanisms will increase the possibility of the control and/or prevention of autoimmune diseases through the use of drugs that target epigenetic pathways. Moreover, we could use epigenetic-related biomarkers to follow this complicated framework (for example H3K4me3 and miRNA-155 are among those proposed biomarkers). This article reviews current understanding of the epigenetic involvement in the field of autoimmune diseases especially in systemic lupus erythematosus, rheumatoid arthritis, sclerosis multiple and type 1 diabetes.


Subject(s)
Autoimmune Diseases/genetics , Epigenesis, Genetic/genetics , Autoimmune Diseases/physiopathology , DNA Methylation/genetics , Histones/genetics , Histones/metabolism , Histones/physiology , Humans , RNA/metabolism , Twins, Monozygotic
3.
Ther Apher Dial ; 19(2): 103-10, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25363837

ABSTRACT

From the 1980s, extracorporeal photochemotherapy (ECP) has been shown to be effective in a variety of pathological conditions such as erythrodermic cutaneous T-cell lymphoma, autoimmune diseases, solid organ allograft rejection and graft versus host disease. To date, ECP represents a non-aggressive immune modulatory therapy with a low spectrum of toxicity. ECP reduces the alloreactivity promoting the immune tolerance to self. At the same time, it allows the maintenance of immune response integrity of both naive and memory T-cells. However, the molecular mechanisms of action by which ECP exerts its therapeutic activity are still under investigation. Here, we review molecular mechanisms and clinical applications involved in ECP. The outcome of ECP is difficult due to the lack of reliable predictor factors for the selection of patients and their adequate follow-up. Since the study of such predictors is important, we also describe some biological markers that enable us to investigate the clinical management of the patients considered for the use of ECP.


Subject(s)
Autoimmune Diseases/therapy , Graft vs Host Disease/therapy , Lymphoma, T-Cell, Cutaneous/therapy , Photopheresis/methods , Humans
4.
Nitric Oxide ; 15(4): 265-79, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16684613

ABSTRACT

Nitric oxide (NO) is a molecule that has gained recognition as a crucial modulator of vascular disease. NO has a number of intracellular effects that lead to vasorelaxation, endothelial regeneration, inhibition of leukocyte chemotaxis, and platelet adhesion. Endothelium damage induced by atherosclerosis leads to the reduction in bioactivity of endothelial NO synthase (eNOS) with subsequent impaired release of NO together with a local enhanced degradation of NO by increased generation of reactive oxygen species with subsequent cascade of oxidation-sensitive mechanisms in the arterial wall. Many commonly used vasculoprotective agents have their therapeutic actions through the production of NO. L-Arginine, the precursor of NO, has demonstrated beneficial effects in atherosclerosis and disturbed shear stress. Finally, eNOS gene polymorphism might be an additional risk factor that may contribute to predict cardiovascular events. However, further studies are needed to understand the possible clinical implications of these correlations.


Subject(s)
Atherosclerosis/physiopathology , Nitric Oxide/physiology , Animals , Humans , Nitric Oxide Synthase Type III/genetics , Nitric Oxide Synthase Type III/metabolism , Polymorphism, Genetic
5.
Exp Oncol ; 27(2): 159-61, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15995637

ABSTRACT

UNLABELLED: Thrombosis is the most frequent complication and the second cause of death in patients with malignant disease. Primary central nervous system non-Hodgkin's lymphoma represents a rare pathology. Resistance to APC is usually linked to a factor V (FV) gene mutation changing an Arg 506 to a Gln in the APC cleavage site. AIM: In our study, we aimed at investigating the presence of activated protein C resistance (APC-r) and other markers of hypercoagulability in 25 selected patients with a diagnosis of primitive cerebral lymphoma who had suffered from an ischemic episode of TIA and/or stroke. PATIENTS AND METHODS: 25 selected patients with a diagnosis of primitive cerebral lymphoma and 50 healthy subjects acted as control group, were tested. We measured APC-r, natural clotting inhibitors, F1 + 2, aPTT and PAI-1 according to international guidelines. Genomic DNA was extracted from peripheral white blood cells and in order to detect FV Leiden gene polymorphism. RESULTS: Our results showed that 11 out of 25 patients had a poor response to APC (< or = 0.70, which represents the cut-off point in our general population) without deficiencies in natural clotting inhibitors. All patients had high plasma levels of F1+2 and PAI-1 compared to those found in healthy subjects (2.65 +/- 0.75 nM/L vs 0.40 +/- 0.35 nM/L; 67.5 +/- 18.5 ng/mL vs 17 +/- 11.5 ng/mL, respectively). In 9 patients resistance to APC was not associated to a FV gene defect demonstrating that such phenomenon may occur also as an acquired condition. However, the patients with resistance to APC showed the highest plasma values in F1 + 2 and PAI-1. CONCLUSION: In cerebral lymphoma with hypercoagulability the resistance to APC is not caused by the FV Arg 506-->Gln mutation (82%). APC resistance not caused by this FV gene defect may be an additional risk factor for thrombophilia in this selected population.


Subject(s)
Activated Protein C Resistance , Biomarkers , Brain Neoplasms/drug therapy , Factor V/genetics , Lymphoma, Non-Hodgkin/drug therapy , Blood Coagulation , Brain Neoplasms/complications , Case-Control Studies , Humans , Ischemic Attack, Transient/etiology , Ischemic Attack, Transient/metabolism , Lymphoma, Non-Hodgkin/complications , Mutation , Peptide Fragments/blood , Phenotype , Plasminogen Activator Inhibitor 1/blood , Prothrombin , Stroke/etiology
6.
Recenti Prog Med ; 96(10): 474-7, 2005 Oct.
Article in Italian | MEDLINE | ID: mdl-16491768

ABSTRACT

The prodromal stage of atherosclerotic lesions is already formed during human fetal development. The presence of infections during childhood may increase synergistically the progression of atherogenesis. After delivery, especially those children exposed to severe maternal hypercholesterolemia should be followed up for the onset and development of acute and chronic infections and be included in clinical and noninvasive examinations of vascular function.


Subject(s)
Atherosclerosis/etiology , Endothelium, Vascular/physiopathology , Infections/complications , Child , Child, Preschool , Chronic Disease , Endothelium, Vascular/microbiology , Endothelium, Vascular/pathology , Female , Fetal Development , Humans , Hypercholesterolemia/complications , Infections/pathology , Infections/physiopathology , Maternal-Fetal Exchange , Pregnancy , Risk Factors
7.
Anesth Analg ; 99(3): 857-863, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15333422

ABSTRACT

We investigated whether intervention with antioxidant vitamins C and E in enteral feeding influenced oxidative stress and clinical outcome in critically ill patients. Two-hundred-sixteen patients expected to require at least 10 days of enteral feeding completed the study. One-hundred-five patients received enteral feeding supplemented with antioxidants, and 111 control patients received an isocaloric formula. Plasma lipoperoxidation (by thiobarbituric acid reactive substances [TBARS] and prostaglandin F(2alpha) isoprostane levels), low-density lipoprotein (LDL) oxidizability, and LDL tocopherol content were determined at baseline and at the end of the 10-day period. The clinical 28-day outcome was also assessed. Plasma TBARS and isoprostanes were 5.33 +/- 1.26 nM/mL and 312 +/- 68 pg/mL, respectively, before treatment and 2.42 +/- 0.61 nM/mL and 198 +/- 42 pg/mL after intervention (P < 0.01 for both comparisons). Antioxidants improved LDL resistance to oxidative stress by approximately 30% (the lag time before treatment was 87 +/- 23 min and was 118 +/- 20 min after treatment; P < 0.04). There was a significantly reduced 28-day mortality after antioxidant intervention (45.7% in the antioxidant group and 67.5% in the regular-feeding group; P < 0.05). Isoprostanes may provide a sensitive biochemical marker for dose selection in studies involving antioxidants.


Subject(s)
Antioxidants/administration & dosage , Enteral Nutrition , Adult , Aged , Critical Illness , Double-Blind Method , Female , Humans , Isoprostanes/blood , Lipid Peroxidation , Male , Middle Aged , Oxidative Stress , Prospective Studies
8.
Proc Natl Acad Sci U S A ; 101(23): 8797-802, 2004 Jun 08.
Article in English | MEDLINE | ID: mdl-15169957

ABSTRACT

The pathogenic mechanisms by which physical exercise influences atherosclerotic lesion formation remain poorly understood. Because vigorous physical training increases oxidative stress, this study tested the hypothesis that graduated and moderate physical exercise together with metabolic intervention (l-arginine and antioxidants) may contribute to increased vascular protection. Exercise training in mice was induced by graduated swimming. In hypercholesterolemic male mice on an atherogenic high-cholesterol diet, graduated and moderate exercise lowered plasma cholesterol and decreased atherosclerotic lesions compared with sedentary control mice. Antioxidants (1.0% vitamin E added to the chow and 0.05% vitamin C added to the drinking water) and l-arginine (6% in drinking water) supplementation to exercising hypercholesterolemic mice further and synergistically reduced atherosclerosis compared with untreated exercised mice. Arterial oxidation-specific epitopes and systemic oxidative stress were reduced by metabolic intervention. Graduated chronic exercise elicited an increase in production of nitric oxide through increased endothelial nitric oxide synthase expression and ameliorated scavenger activities. Thus, metabolic intervention with l-arginine and antioxidants together with graduated and moderate exercise training reduce atherosclerotic lesion formation.


Subject(s)
Antioxidants/therapeutic use , Arteriosclerosis/prevention & control , Hyperlipoproteinemia Type II/complications , Hyperlipoproteinemia Type II/therapy , Physical Conditioning, Animal , Animals , Arginine/therapeutic use , Arteriosclerosis/etiology , Arteriosclerosis/metabolism , Ascorbic Acid/therapeutic use , Diet, Atherogenic , Hyperlipoproteinemia Type II/metabolism , Male , Mice , Mice, Knockout , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , Nitric Oxide Synthase Type III , Oxidative Stress , Receptors, LDL/deficiency , Receptors, LDL/genetics , Vitamin E/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...